YSPSL for Prevention of Delayed Graft Function Part A
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Selectins have been implicated in the pathogenesis of ischemia/reperfusion (I/R)-induced
kidney injury and resultant DGF. PSGL-1 is a ligand for P-, E-, and L-selectin. It has been
reported that that YSPSL (rPSGL-Ig) blocks P-selectin and, to a lesser degree, E- and
L-selectin. Both sPSGL-1 and YSPSL (rPSGL-Ig) have been shown in animal models to reduce both
cytokines and tissue damage associated with ischemia reperfusion and to improve renal
function post-transplant. Therefore, the current phase I/II clinical study is designed to
assess the safety and efficacy of YSPSL (rPSGL-Ig) in preventing DGF in patients undergoing
cadaveric kidney transplants and to determine a dose for future pivotal studies.